- Conditions
- Bipolar Depression
- Interventions
- Lumateperone, Placebo
- Drug
- Lead sponsor
- Intra-Cellular Therapies, Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 56
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 38 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 8,604
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Traumatic Brain Injury, Alexithymia
- Interventions
- TREAT
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Obstructive Sleep Apnea, Obesity
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Riverside, California • Brandon, Florida • Ocala, Florida + 15 more
- Conditions
- Post Operative Pain
- Interventions
- oxymorphone HCl
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 0 Years to 12 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Aurora, Colorado + 5 more
- Conditions
- Ischemic Ventricular Tachycardia
- Interventions
- Therapy Cool Path Duo Cardiac Ablation System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Maywood, Illinois • Indianapolis, Indiana + 2 more
- Conditions
- Diarrhea, Drug/Agent Toxicity by Tissue/Organ, Neuroblastoma
- Interventions
- cefixime, irinotecan hydrochloride, temozolomide
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Intervention Group, Treatment as Usual
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Denture Retention
- Interventions
- Test Product, Positive Contol, Negative Control
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
- Interventions
- Zenith(R) Fenestrated AAA Endovascular Graft
- Device
- Lead sponsor
- Cook Group Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 14
- States / cities
- San Francisco, California • Gainesville, Florida • Indianapolis, Indiana + 11 more
- Conditions
- Fibromyalgia
- Interventions
- Yoga, Structured Exercise
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Neoplasms
- Interventions
- DSP-0337
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • San Antonio, Texas + 1 more
- Conditions
- Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Cisplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, External Beam Radiation Therapy, Filgrastim, Laboratory Biomarker Analysis, Melphalan, Mesna, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Topotecan Hydrochloride, Vincristine Sulfate
- Procedure · Drug · Radiation + 2 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Downey, California • Duarte, California + 90 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more
- Conditions
- Migraine
- Interventions
- AMG 334 Dose 1, AMG 334 Dose 2, AMG 334 Dose 3
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Stamford, Connecticut + 11 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 53 more
- Conditions
- Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
- Interventions
- Everolimus, Paclitaxel
- Drug
- Lead sponsor
- Matthew Galsky
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more
- Conditions
- Arrythmia, Cardiomyopathies
- Interventions
- Intra-Op Prophylactic VT ablation, Conventional Management
- Procedure · Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Ovarian Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Levonorgestrel, Placebo
- Other · Drug
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 66
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 46 more
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
- Interventions
- IDE-161, Pembrolizumab
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Interventions
- Integrated Metacognitive Therapy, Treatment as Usual
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
- Interventions
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- Treatment Planning using the DIBH Technique
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
- Interventions
- Levosimendan, Placebo
- Drug
- Lead sponsor
- Tenax Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 882 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
- Conditions
- Lupus Nephritis
- Interventions
- Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 11
- States / cities
- Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more